Three States File Petition to Reverse Trump Medical Cannabis Rule

The Legal Challenge

The three-state coalition filed its petition for review in the U.S. Court of Appeals for the D.C. Circuit, targeting the DEA's April 15, 2026 final rule that created a dual-schedule system for cannabis. The 42-page filing argues the Drug Enforcement Administration exceeded its statutory authority under the Controlled Substances Act by assigning a single substance to two schedules simultaneously based on end-use rather than pharmacology.

California Attorney General Rob Bonta, New York Attorney General Letitia James, and Illinois Attorney General Kwame Raoul signed the petition. Together, the states operate a combined 2,800 licensed dispensaries serving both medical and adult-use markets under state law.

The Split-Schedule Framework

The DEA's April rule placed cannabis in Schedule III when sold through state-licensed medical programs and kept it in Schedule I for all recreational sales. The states call this administratively impossible to enforce. Medical cannabis means products sold to patients holding valid state medical cards and purchased from dispensaries licensed under medical programs predating 2024.

Recreational products—even chemically identical flower—remain Schedule I. The distinction hinges entirely on the purchaser's credential and the dispensary's license type. Not the substance's molecular composition. Not its abuse potential.

The States' Core Argument

The petition argues the Controlled Substances Act requires scheduling decisions to rest on a drug's pharmacological properties, not its distribution channel or consumer identity. Section 811 of the CSA directs the Attorney General to consider eight factors when scheduling a substance: actual or relative potential for abuse, scientific evidence of pharmacological effect, state of current scientific knowledge, history and current pattern of abuse, scope/duration/significance of abuse, and risk to public health.

None of those factors permits the DEA to classify the same molecule differently based on whether the buyer shows a medical card, the states contend. The petition cites the Supreme Court's 2005 Gonzales v. Raich decision, which treated cannabis as a single substance for Commerce Clause purposes.

The 280E Tax Trap

The dual-schedule system creates immediate tax consequences under IRC Section 280E, which bars business-expense deductions for trafficking in Schedule I or II substances. Medical dispensaries would gain access to standard business deductions—payroll, rent, utilities. Recreational operators selling identical products would continue operating under 70-80% effective tax rates.

California's petition estimates the rule would shift $1.2 billion in annual tax liability from medical to recreational operators in that state alone. Dual-license operators—dispensaries serving both patient types under one roof—face what the filing calls "an accounting nightmare with no statutory basis."

Interstate Commerce Concerns

The states argue the rule violates the Commerce Clause by creating a patchwork that effectively prohibits interstate medical cannabis commerce even if Congress were to permit it. Seventeen states lack medical programs that meet the DEA's pre-2024 licensing threshold. Patients in those states would have no legal access to Schedule III cannabis even under a hypothetical federal framework allowing medical interstate sales.

The petition also flags conflicts with the 2018 Farm Bill's hemp provisions. Hemp-derived delta-9 THC products sold as dietary supplements would remain unscheduled, while dispensary-sold cannabis flower testing at 0.2% delta-9 THC would be Schedule III or I depending on the buyer's credential. For context on the hemp-cannabis divide, see the CannIntel topic hub on cannabis rescheduling legal challenges.

Industry and Operator Impact

The National Cannabis Industry Association filed an amicus brief supporting the states, arguing the rule forces operators to choose between state compliance and federal classification. Multistate operators with both medical and recreational licenses would need to maintain separate supply chains, separate inventories, and separate compliance systems for chemically identical products.

The brief estimates compliance costs at $40,000-$80,000 per dual-license location annually. Testing labs would be required to certify not just cannabinoid content but also the end-user's credential status—a data point labs don't currently track and have no chain-of-custody mechanism to verify.

What Happens Next

The D.C. Circuit will likely consolidate this petition with at least four other challenges filed by industry groups and individual operators in April and May 2026. The court hasn't yet set a briefing schedule. The DEA's rule took effect May 1, 2026, meaning the dual-schedule system is currently operative unless the court issues a stay.

The states requested oral argument. A three-judge panel assignment is expected by mid-June. If the court follows the timeline of the 2020 Americans for Safe Access v. DEA case, a decision could come in late 2026 or early 2027. Until then? Expect enforcement to vary sharply by jurisdiction—and by whether the product crosses a dispensary counter with or without a medical card in hand.